Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Cuts Q3 Revenue Guidance 8-12 Percent on Soft Sales

NEW YORK (GenomeWeb News) – Soft sales during the third quarter has forced Molecular Devices to cut its financial guidance for the period by between 8 percent and 12 percent, the company said today.
 
Molecular Devices said it now expects revenue for the three months ended Sept. 30 to be between $44 million and $46 million. In July the company said it expected to generate between $48 million and $52 million in the period.
 
Third-quarter 2005 revenues were $45.2 million.
 
Molecular Devices in July also cut its full-year 2006 guidance to between $190 million and $198 million from between $198 million and $206 million.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.